Rheumatology and Therapyis an international, open access, peer-reviewed (single-blind), and rapid publication journal, dedicated to the publication of high-quality clinical (all phases), observational, real-world and health outcomes research around the discovery, development, and use of therapies for rheumatic diseases. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also welcomed.
Rapid publication: The journal aims for a 2-week peer review, 3-4 weeks from acceptance to online.
Open access:All articles published open access (CC-BY-NC)
Inclusivity:All scientifically sound research considered be it positive, confirmatory or negative data. Research is considered from pre-clinical, clinical phase, real-world and health economics outcomes studies. Submissions are welcomed whether they relate to an international or a country-specific audience.
Personal service: The journal’s team will re-format articles and upload submissions on behalf of authors, if necessary.
Digital Features and Plain Language Summaries:These peer-reviewed features are welcomed to help enhance the educational value of a manuscript (for more information see “Author Information – Guidelines for digital features and plain language summaries” under “Submission guidelines”). For examples of digital features please visit:
Publication fees: Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5,250/$6,000/£4,300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis.
Contact: For more information about the journal, including pre-submission enquiries, please contact David Gray at email@example.com.
- Publishing model
- Open Access. Learn about publishing OA with us
- 3.494 (2020)
- Impact factor
- 4.613 (2020)
- Five year impact factor
- 17 days
- Submission to first decision
- 42 days
- Submission to acceptance
- 172,188 (2020)
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Authors (first, second and last of 14)
Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study
Authors (first, second and last of 31)
About this journal
- Electronic ISSN
- Print ISSN
- Abstracted and indexed in
- Current Contents/Clinical Medicine
- EBSCO Academic Search
- EBSCO Discovery Service
- Google Scholar
- Journal Citation Reports/Science Edition
- OCLC WorldCat Discovery Service
- ProQuest-ExLibris Primo
- ProQuest-ExLibris Summon
- Science Citation Index Expanded (SciSearch)
- Semantic Scholar
- TD Net Discovery Service
- UGC-CARE List (India)